Annual Meeting Recordings are now available for purchase
311641
Agenda Setting for Public Health Law: Identifying Critical Opportunities
Monday, November 17, 2014
: 10:30 AM - 10:45 AM
Michelle Mello, JD, PhD
,
Stanford Law School and Stanford University School of Medicine, Stanford University, Stanford, CA
Although legal interventions are responsible for many sentinel public health achievements, law is underutilized as a tool for advancing population health. Because of information gaps, industry opposition, failure to capture lawmakers’ attention, and other factors, there are legal interventions that could powerfully affect a broad range of health threats, yet are not widely disseminated or well implemented. Making more intelligent use of law requires a framework in which researchers and policymakers can think strategically, apply common criteria to set a policy agenda, and marshal evidence to identify the most promising avenues for action. This presentation will offer such a framework, the Critical Opportunities approach, and discuss its benefits as an evaluative tool. Key challenges, such as determining the level of evidence that is sufficient to justify moving forward with a new legal intervention, will be discussed. Finally, it will take on the broader normative question of when, and on what basis, legal regulation can be ethically and politically justified.
Learning Areas:
Public health or related laws, regulations, standards, or guidelines
Public health or related public policy
Public health or related research
Learning Objectives:
Identify critical opportunities to use legal interventions to improve public health.
Keyword(s): Law, Policy/Policy Development
Presenting author's disclosure statement:Qualified on the content I am responsible for because: I am a member of the Methods Core of RWJF's National Program on Public Health Law Research, and the lead author of the paper on which this presentation is based.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines,
and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed
in my presentation.